Paul Biondi

Paul is an Executive Partner at Flagship Pioneering and President of Pioneering Medicines, a strategic initiative that harnesses the power of Flagship’s scientific bioplatforms to conceive and develop an innovative pipeline of life-changing treatments for patients. Pioneering Medicines also engages with the broader biopharma industry through novel strategic partnerships to jointly conceive new products by combining partner’s R&D priorities with Flagship's full spectrum of unique platform capabilities and innovation, as well as the drug development expertise of the Pioneering Medicines team. Current partners include the Cystic Fibrosis Foundation, Novo Nordisk, and Pfizer.

In his role at Flagship, Paul also works with growth company CEOs and their teams to achieve the best attainable value for each company. He serves on the boards of Flagship-founded companies including Seres Therapeutics (NASDAQ: MCRB) and Valo Health.

Paul joined Flagship Pioneering following a seventeen-year tenure at Bristol-Myers Squibb (BMS). He served as the Senior Vice President of Strategy and Business Development where he had enterprise-wide responsibility for establishing and evolving BMS’s strategy, and for pursuing strategic transactions to access external innovation, enhance BMS’s capabilities and strengthen the company’s portfolio. Prior to this role, Paul held a series of leadership roles within BMS’ R&D organization overseeing strategy, portfolio and project management, and clinical and business operations. Paul previously spent nine years at Mercer Management Consulting.

Paul received his M.B.A. from the J.L. Kellogg School of Management at Northwestern University and his B.A. from Dartmouth College.